Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients

Liver Transplantation

Volumn 7, Issue 2, 2001, Pages 93-99

  Manzarbeitia, Cosme ^a   Reich, David J ^a   Rothstein, Kenneth D ^a   Braitman, Leonard E ^a   Levin, Scott ^a   Munoz, Santiago J ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CHOLESTEROL; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN; PREDNISONE; TACROLIMUS; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HERPES ZOSTER; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LONG TERM CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RASH; RECIPIENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035118491     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.21289     Document Type: Article

References (40)

1. The 12th Report of the Human Renal Transplant Registry
2. Acute myocardial infarction in renal transplant recipients: Incidence and prognosis
3. Deaths from occlusive arterial disease in renal allograft recipients
4. Lipid mediators in organ transplantation: Does cyclosporine accelerate coronary atherosclerosis?
5. Hyperlipidemia following heart transplantation: Natural history and intervention with mevinolin (Lovastatin)
6. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations
7. Lipoprotein (a) and apolipoprotein changes after cardiac transplantation
8. Hyperlipidemia in adult, pediatric and diabetic renal transplant recipients
9. Lipid abnormalities in pediatric hepatic allograft recipients
10. Hyperlipidemia and obesity after orthotopic liver transplantation
11. Hyperlipidemia after renal transplantation: Natural history and pathophysiology
12. Prevalence of dyslipidemia in liver transplant recipients
13. Prevalence of hyperlipidemia in heart transplant recipients
14. Lovastatin treatment of hypercholesterolemia in renal transplant recipients
15. Lipoprotein abnormalities in long-term stable liver and renal transplant patients. A comparative study
16. Serum cholesterol changes in long-term survivors of liver transplantation: A comparison between cyclosporine and tacrolimus therapy
17. Hyperlipidemia in liver transplant recipients: Prevalence and risk factors
18. Metabolic problems in recipients of liver transplants
19. Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506)
20. Risk factors for premature coronary heart disease after successful liver transplantation in adults
21. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity
22. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation
23. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after transplantation
24. Hyperlipidemia after liver transplantation: Natural history and treatment with the hydroxy-methylglutaryl-co-enzyme A reductase inhibitor pravastatin
25. Lipoprotein cholesterol distributions in selected North American populations. The Lipid Research Clinics Study
26. Alterations in lipid and carbohydrate metabolism attributable to cyclosporine A in renal transplant recipients
27. Effects of cyclosporine therapy on plasma lipoprotein levels
28. Kidney transplantation under FK506
29. Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s
30. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss
31. Who should be converted from cyclosporine to conventional immunosuppression in kidney transplantation, and why
32. A randomized trial of primary liver transplantation under immunosuppression with FK506 versus cyclosporine
33. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients
34. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
35. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
36. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
37. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: A Southeastern Organ Procurement Foundation multicenter clinical study
38. Conversion of liver allograft recipients from cyclosporine to FK506-based immunosuppression: Benefits and pitfalls
39. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: Pathogenesis, diagnosis and management